当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2019年第16期
编号:13372336
SIRT1在非小细胞肺癌TKIs获得性耐药中的调控作用(5)
http://www.100md.com 2019年6月5日 《中国医药导报》 2019年第16期
     [20] Yang H,Bi Y,Xue L,et al. Multifaceted Modulation of SIRT1 in Cancer and Inflammation [J]. Crit Rev Oncog,2015,20(1/2):49-64.

    [21] Raffaele P,Mauro C,David DM,et al. Sirtuins and Cancer:Role in the Epithelial-Mesenchymal Transition [J]. Oxid Med Cell Longev,2016,2016:1-9.

    [22] Li L,Osdal T,Ho Y,et al. SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells [J]. Cell Stem Cell,2014,15(4):431-446.

    [23] Zeisig B,So C. A Knockout Combo:Eradicating AML Stem Cells with TKI plus SIRT1 Inhibition [J]. Cell Stem Cell,2014,15(4):395-397.

    [24] Zhang W,Gao C,Konopleva M,et al. Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies [J]. Clin Cancer Res,2014,20(9):2363-2374.

    [25] Powell MJ,Casimiro MC,Carlos CC,et al. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation [J]. Cancer Res,2011,71(3):964-975., http://www.100md.com(李桂芳 原翔 刘怡文 马名扬 孙江涛)
上一页1 2 3 4 5